I agree. I think the UK’s new accelerated program likely means that the MHRA has had a plan in place for some time now. I think it looks to me like at the highest levels, there is an expectation to make this available asap. I think the FDA will experience some pressure here to accelerate their activity and get this available to patients. I do not expect years of delay as the advance here is too important for GBM patients.
If there is truly a delay by “design” then that certainly wouldn’t be initiated by the company. To me that would be somewhat worrisome if that is true.